Related Experiment Video
Updated: Jul 7, 2026

Monitoring Dynamic Growth of Retinal Vessels in Oxygen-Induced Retinopathy Mouse Model
Published on: April 2, 2021
ELAVL1 Stabilizes HMOX1 mRNA to Drive Ferroptosis in Diabetic Retinopathy
Yanjun Gao1, Wenjing Zhao2, Qiannan Chai1
1Department of Ophthalmology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050000, People's Republic of China.
Objective:
This study aims to investigate the role of heme oxygenase 1 (HMOX1) in the pathogenesis of diabetic retinopathy (DR) and identify the RNA-binding protein embryonic lethal abnormal vision-like 1 (ELAVL1) as a novel regulator of HMOX1 mRNA stability driving ferroptosis, proposing ELAVL1 as a potential therapeutic target for DR.
Methods:
DR was modeled in vitro using high glucose (HG)-treated ARPE19 cells and in vivo via streptozotocin (STZ)-induced diabetic rats. Cell damage was assessed through measuring cell viability, oxidative stress markers, iron content, and ferroptosis-related protein expression. HMOX1 expression and its regulatory interaction with ELAVL1 were analyzed using RT-qPCR, immunohistochemistry, Western blotting, RNA-fluorescence in situ hybridization, and RNA immunoprecipitation. Functional roles were validated by gene knockdown or overexpression experiments.
Results:
HG stimulation induced ferroptosis-related damage and oxidative stress in ARPE19 cells and the retinas of DR rats, accompanied by a significant upregulation of HMOX1 expression (approximately 165% in vivo and 189% in vitro). Knockdown of either HMOX1 or ELAVL1 effectively suppressed ferroptosis and mitigated retinal degeneration.
Conclusion:
HMOX1 is critical for ferroptosis-mediated retinal damage in DR, and ELAVL1 promotes ferroptosis predominantly by stabilizing HMOX1 mRNA.
More Related Videos
06:51Retinal Explant of the Adult Mouse Retina as an Ex Vivo Model for Studying Retinal Neurovascular Diseases
Published on: December 9, 2022
04:01Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics
Published on: March 15, 2024